TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04778618
Drug: Antithymocyte Globulin
Normalized name: Rabbit antithymocyte globulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual dose of ATG was Intravenous infused every day from day -5 to day -2 (total ATG dose was calculated based on pharmacokinetic index, within a range of 6 mg/kg to 10mg/kg). Antithymocyte globulin (ATG) was added to conditioning regimens for 4 days (days -5 and -2). Prophylaxis against graft-versus-host disease (GVHD) was performed with cyclosporine A (CsA), mycophenolate mofetil (MMF) and short-term methotrexate
Study: NCT00204022
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil
Study: NCT00977548
Drug: Erlotinib
Normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants took erlotinib at least 1 hour before, or 2 hours after they ate a meal or snack. Participants were advised to take erlotinib at around the same time every day.
Study: NCT00377078
Drug: recombinant human lactoferrin
Normalized name: lactoferrin (synthetic human)
DrugBank: Lactoferrin (DB16555)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02719795
Drug: Ropivacaine
Normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Local injection of local anesthetic into the fascial spaces
Study: NCT01372124
Drug: NOX-E36
Normalized name: NOX-700
DrugBank: NOX-700 (DB05464)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All subjects included in this study will receive the same dose of NOX E36. In previous clinical trials, single intravenous doses of NOX E36 up to 2 mg/kg body weight and single subcutaneous doses of up to 0.5 mg/kg body weight appeared to be safe and well tolerated in healthy volunteers. Pharmacokinetic analyses have shown dose linearity
Study: NCT03173170
Drug: TAK-954
Normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-954 Infusion
Study: NCT03173170
Drug: Itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Itraconazole Capsule
Study: NCT00150553
Drug: Extended-release carbamazepine
Normalized name: carbamazepine Extended Release Oral Capsule
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02618382
Drug: Tranexamic Acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1300mg tranexamic acid by mouth once before surgery and then three times a day for up to three days or until they are discharged from the hospital, whichever comes first
Study: NCT01470417
Drug: Chemotherapy + ChemoRadiotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nab-paclitaxel 100 mg/m2 IV over 30 minutes on days 1, 8, and 15 along with gemcitabine 1000 mg/m2 IV over 30 minutes on days 1, 8, and 15 in an every 28 day cycle for two cycles. Subjects with high-risk or borderline resectable disease will receive additional chemotherapy with radiation therapy prior to resection.
Study: NCT00002616
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002616
Drug: thiotepa
Normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00972907
Drug: Nifedipine coated suppositories
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12 mg Nifedipine coated suppositories BID
Study: NCT04249778
Drug: Dapagliflozin
Normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Participants will receive 10 mg/day of dapagliflozin, beginning at hospital discharge, for 26 weeks.
Study: NCT03500367
Drug: rapamycin
Normalized name: Rapamycin
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: rapamycin, 2 mg a day, orally ,for 3months
Study: NCT03399084
Drug: Ferric carboxymaltose
Normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 750 mg/15 mL
Study: NCT02044250
Drug: Clopidogrel
Normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Clopidogrel 75mg 1tab P.O. daily
Study: NCT02044250
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin 100\~200mg 1\~2tab P.O. daily
Study: NCT02418455
Drug: UX003
Normalized name: Vestronidase alfa
DrugBank: Vestronidase alfa (DB12366)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: solution for intravenous infusion
Study: NCT03223909
Drug: Systane Ultra
Normalized name: Systane Ultra
DrugBank: Propylene glycol (DB01839)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Is a sterile solution containing polyethylene glycol 400, propylene glycol, hydroxypropyl-guar, sorbitol, aminomethylpropanol, boric acid, potassium chloride, sodium chloride and POLYQUAD® (poly-hydronium chloride) 0.001% as preservative.
Study: NCT03223909
Drug: Systane Ultra Preservative Free
Normalized name: Systane Ultra Preservative Free
DrugBank: Propylene glycol (DB01839)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Polyethylene Glycol 400 0.4%Lubricant, Propylene Glycol 0.3% Lubricant,
Study: NCT02066337
Drug: Ozonated olive oil gel
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04157478
Drug: Anlotinib Hydrochloride
Normalized name: Erlotinib Hydrochloride
DrugBank: Anlotinib (DB11885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anlotinib hydrochloride will be given with a daily dose of 12 mg for 14 days of a 21-day cycle up to 2 cycles, initiated on the first day of radiation therapy and followed by adjuvant treatment with the same dosing schedule until patients have disease progression or intolerable toxicities.
Study: NCT04157478
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Temozolomide will be administered at a daily dose of 75 mg/m2 until the completion of radiation therapy. Four weeks after the completion of radiation therapy, patients will be given with adjuvant chemotherapy with temozolomide at a dose of 150-200 mg/m2 for 5 days of a 28-day cycle for a total of 6 cycles.
Study: NCT01953887
Drug: EC905
Normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral
Study: NCT01953887
Drug: solifenacin
Normalized name: Solifenacin
DrugBank: Solifenacin (DB01591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral
Study: NCT01953887
Drug: tamsulosin
Normalized name: Tamsulosin
DrugBank: Tamsulosin (DB00706)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral
Study: NCT04003818
Drug: TEICOPLANIN
Normalized name: teicoplanin
DrugBank: Teicoplanin (DB06149)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:solution for oral administration Route of administration: oral
Study: NCT03451006
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral metformin (up to 2gm) will be given in divided doses
Study: NCT01704937
Drug: Fecal Microbiota Transplant (FMT)
DrugBank: Fecal microbiota (DB17743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reconstitution of normal flora by a stool transplant from a healthy individual to a C. difficile - infected recipient via colonoscopy or nasogastric tube
Study: NCT01413763
Drug: Imiquimod cream 3.75%
DrugBank: Imiquimod (DB00724)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 3.75% cream, applied daily for 2 weeks
Study: NCT01049347
Drug: amitriptyline
Normalized name: Amitriptyline
DrugBank: Amitriptyline (DB00321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 150 mg oral, daily, single evening dose, 35 days
Study: NCT01049347
Drug: paroxetine
Normalized name: Paroxetine
DrugBank: Paroxetine (DB00715)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40 mg oral, single dose, morning, 35 days
Study: NCT03485482
Drug: Bisoprolol
Normalized name: Bisoprolol
DrugBank: Bisoprolol (DB00612)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: bisoprolo 5 mg tablets
Study: NCT03485482
Drug: Ivabradine
Normalized name: Ivabradine
DrugBank: Ivabradine (DB09083)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ivabradine 10 mg tablet
Study: NCT03485482
Drug: combination of Ivabradine and bisoprolol
Normalized name: carvedilol and ivabradine
DrugBank: Bisoprolol (DB00612)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: combination of 10 mg ivabradine and 5 mg bisoprolol
Study: NCT02276768
Drug: GIC-1002 345 mg TID (equimolar to GIC-1001 375 mg TID)
Normalized name: elacestrant
DrugBank: Elacestrant (DB06374)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GIC-1002 345 mg TID mid-dose, oral tablet, white-coated, to be taken with water
Study: NCT02276768
Drug: GIC-1002 460 mg (equimolar to GIC-1001 500 mg)
Normalized name: calcium carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GIC-1002 460 mg TID high-dose, oral tablet, white-coated, to be taken with water
Study: NCT03367689
Drug: Olaparib
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib 300 mg twice a day (orally) beginning on Day 1 and continuing through Day 28 of every 28-day cycle.
Study: NCT02127073
Drug: Intranasal Oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal spray, one spray or 4 IU of oxytocin will be administered into each nostril of each patient about 15-30 minutes before NAF collection
Study: NCT01221831
Drug: estetrol, P 1 and placebo tablets
DrugBank: Estetrol (DB12235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 6 treatment cycles each consisting of 28 days of oral administration as follows:~* Days 1-24: one estetrol tablet and one P1 tablet per day~* Days 25-28: two placebo tablets per day
Study: NCT01221831
Drug: estetrol, P2 and placebo tablets
DrugBank: Estetrol (DB12235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 6 treatment cycles each consisting of 28 days of oral administration as follows:~* Days 1-24: one estetrol tablet and one P2 tablet per day~* Days 25-28: two placebo tablets per day
Study: NCT02506231
Drug: Folinic acid
Normalized name: Folinic acid
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00724620
Drug: Ribavirin (SCH 018908)
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: All patients will receive peginterferon alfa-2b 1.5 ug/kg administered subcutaneously (SC) once weekly in combination with ribavirin (800-1200 mg/day) administered orally (PO) for a minimum period of 12 weeks. The total treatment duration will be as follows: 48 weeks for Early Responders, 72 weeks for Slow Responders, and 12 weeks for Nonresponders.
Study: NCT03988101
Drug: Control
Normalized name: Control
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients who are eligible for all of the criteria and who do not qualify as exclusion criteria should be enrolled in the study and randomly enrolled in a 1: 1 dose of rosuvastatin 20 mg once daily or equivalent.
Study: NCT00062101
Drug: erlotinib hydrochloride
Normalized name: Erlotinib Hydrochloride
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally (PO)
Study: NCT01293266
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anesthesia is switched from sevoflurane to propofol after obtaining a baseline blood gas analysis.
Study: NCT03176784
Drug: Varenicline
Normalized name: Varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5mg and 1.0 mg pills used. See arms for specific durations. (Active and placebo varenicline pills provided at no cost through an independent research agreement with Pfizer.)
Study: NCT03176784
Drug: Nicotine patch
Normalized name: Nicotine Patch
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 14 mg and 7 mg nicotine patches used. See arms for specific durations.
Study: NCT02466802
Drug: Regorafenib
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Combination of regorafenib and of sildenafil when given to patients with advanced solid tumors. Regorafenib Administration and Treatment Schedule. Regorafenib will be taken orally once daily for the first 21 days of each 28-day cycle. Regorafenib will not be taken on the last 7 days of each cycle. Patients will be instructed as follows: Take regorafenib once daily with a low fat meal that contains less than 30% fat. Take the regorafenib tablets at about the same time each day. Swallow the tablets whole.
Study: NCT02466802
Drug: Sildenafil Citrate
Normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combination of regorafenib and of sildenafil when given to patients with advanced solid tumors.Sildenafil Administration and Treatment Schedule. Sildenafil will be taken orally once daily at the same time the regorafenib dose is taken for the first 21 days of each 28-day cycle. Sildenafil will not be taken on the last 7 days of each cycle.
Study: NCT00921284
Drug: dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 mcg/kg administered in 10 minutes followed by a continuous infusion of 0,5 mcg/kg/hr
Study: NCT01935479
Drug: AK159
Normalized name: Azelastine hydrochloride
DrugBank: Azelastine (DB00972)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: transdermal administration of teriparatide acetate
Study: NCT02990806
Drug: NI-071
Normalized name: Toto ni vavalagi oil
DrugBank: Castor oil (DB11113)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion.
Study: NCT02990806
Drug: Remicade
Normalized name: Remicade
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV infusion.
Study: NCT03389087
Drug: Apatinib and Etoposide Capsule
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Apatinib 250mg/qd，po, A course of treatment need 28 days. Etoposide Capsule 25mg/d，po, from day 1-day 21.
Study: NCT00108576
Drug: Divalproex
Normalized name: DIVALPROEX
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: anticonvulsant; mood stabilizer
Study: NCT00003894
Drug: thalidomide
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02676791
Drug: Povidone-Iodine
Normalized name: Povidone-Iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A standard nasogastric tube will be inserted into all patients after induction of general anesthesia. After surgical dissection, the esophagus / stomach will be cut at the desired level leaving the tip of the nasogastric tube proximal to the esophageal carcinoma. Then, 50ml of a 11% povidone-iodine solution (Betaisodona®, Mundipharma) will be introduced into the esophagus via the nasogastric tube and evacuated with a suction device (washout). The nasogastric tube will then be removed for completion of esophageal resection and beginning of reconstruction.
Study: NCT01526460
Drug: Atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 80 mg
Study: NCT00895037
Drug: ReFacto AF (Moroctocog alfa)
Normalized name: Moroctocog alfa
DrugBank: Moroctocog alfa (DB13999)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Patients will be treated with intravenous infusion of ReFacto AF per dosing and frequency as prescribed by the subjects' treating physician. ReFacto AF® will be prescribed in the context of routine clinical practice in Germany and Austria, respectively
Study: NCT00414349
Drug: Topical analgesic
Normalized name: Tricylate 2%-10% Topical Analgesic Cream
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: max. 3 plasters per day for PHN patients max. 4 plasters per day for DPN patients
Study: NCT00414349
Drug: Topical analgesic
Normalized name: Tricylate 2%-10% Topical Analgesic Cream
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3 plasters for PHN patients per day 4 plasters for DPN patients per day
Study: NCT01029392
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2000iu once a day
Study: NCT00913003
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine bolus infusion 1.5 mg/kg IV using participants IBW(Ideal Body Weight) Lidocaine infusion after bolus and continuing until 1 hour after skin closure 33.3 mcg/kg/mn IV (IBW)
Study: NCT02377466
Drug: Retosiban IV infusion
Normalized name: atosiban
DrugBank: Retosiban (DB11818)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Retosiban for IV administration will be supplied as solution for infusion, consisting of a clear colorless solution of retosiban at a concentration of 15 milligram per milliliter (mg/mL).
Study: NCT04449536
Drug: Mesna
Normalized name: Mesna
DrugBank: Coenzyme M (DB09110)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration of a single oral dose, using film-coated tablets of either 400 mg or 600 mg or a combination of maximum 3 tablets up to a maximum of 1600 mg
Study: NCT04100096
Drug: Brexpiprazole
Normalized name: Brexpiprazole
DrugBank: Brexpiprazole (DB09128)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tablet
Study: NCT00063973
Drug: cilengitide
Normalized name: Cilengitide
DrugBank: Cilengitide (DB11890)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT02104817
Drug: corn oil control
Normalized name: Corn Oil
DrugBank: Corn (DB10572)
Approvals — FDA: no, EMA: no, PMDA: no
Description: corn oil control arm
Study: NCT01225055
Drug: Teriparatide
Normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 20 ug daily over 12 months
Study: NCT00000555
Drug: estrogen replacement therapy
Normalized name: estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00000555
Drug: estrogens, conjugated
Normalized name: ESTROGENS, CONJUGATED
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00000555
Drug: progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00000555
Drug: hormone replacement therapy
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00000555
Drug: vitamin e
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00114231
Drug: oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00005937
Drug: Antithymocyte globulin
Normalized name: Rabbit antithymocyte globulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithymocyte globulin (ATG) intravenous infusion: 40mg/kg/day. Infusion over 6 hours on day 1-4.
Study: NCT02137382
Drug: Creon N
Normalized name: Creon
DrugBank: Pancrelipase amylase (DB11065)
Approvals — FDA: no, EMA: no, PMDA: no
Description: experimental drug
Study: NCT02985619
Drug: Bevacizumab Injection [Avastin] (IVB-I)
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 0,05ml intravitreal injection
Study: NCT02985619
Drug: Triamcinolone Acetonide 10mg/mL (IVT-II)
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0,03ml intravitreal injection
Study: NCT02985619
Drug: Bevacizumab Injection [Avastin] (IVB-III)
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 0,05ml intravitreal injection
Study: NCT01933919
Drug: Fluvoxamine maleate
Normalized name: Fluvoxamine Maleate
DrugBank: Fluvoxamine (DB00176)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Film-coated tablet containing 25 mg of fluvoxamine maleate
Study: NCT00005937
Drug: Cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine (CsA) intravenous infusion: 5mg/kg. Infusion on day 14 administered twice a day.
Study: NCT01684215
Drug: PD-0332991
Normalized name: dolutegravir
DrugBank: Dolutegravir (DB08930)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PD-0332991 (100 mg or 125 mg) will be orally administered once a day for 3 weeks followed by 1 week off treatment, in the morning on an empty stomach. Dose reduction of PD-0332991 by one (100 mg) or two (75 mg) dose level is permitted depending on treatment related toxicity.
Study: NCT01684215
Drug: PD-0332991
Normalized name: dolutegravir
DrugBank: Dolutegravir (DB08930)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PD-0332991, 125 mg, will be orally administered with food once a day for 3 weeks followed by 1 week off treatment. PD-0332991 will be administered once a day together with letrozole. Dose reduction of PD-0332991 by one (100 mg) or two (75 mg) dose level is permitted depending on treatment related toxicity.
Study: NCT01684215
Drug: letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Letrozole, 2.5 mg, will be orally administered once a day in continuous daily dosing together with PD-0332991. Dose reduction of letrozole is not permitted, but dosing interruptions for letrozole-related toxicity are allowed as per investigator's medical judgement.
Study: NCT00401167
Drug: memantine
Normalized name: Memantine
DrugBank: Memantine (DB01043)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Following the baseline visit, subjects will receive memantine 5 mg OD for one week, followed by 5 mg BID for one week, followed by 10 mg QAM and 5 mg QPM for one week, followed by 10 mg BID for the following 9 weeks.
Study: NCT01593072
Drug: AVI-7537
Normalized name: AVI-7537
DrugBank: AVI-7537 (DB15433)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohort 1: AVI-7537 at 4.5 mg/kg IV; Cohort 2: AVI-7537 at 9 mg/kg IV;Cohort 3: AVI-7537 at 15 mg/kg IV; Cohort 4: AVI-7537 at 30 mg/kg IV~The amount of AVI-7537 required to administer the required dose will be diluted to a volume of approximately 150 mL with normal saline solution (NSS) and given by IV infusion over 30 minutes once a day for 14 days. Infusions will be administered at approximately the same time each day.
Study: NCT00852917
Drug: Tramadol Once A Day
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One Tramadol Once A Day tablet at randomized dose daily.
Study: NCT00005090
Drug: carmustine
Normalized name: Carmustine
DrugBank: Carmustine (DB00262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 150/m\^2 on days -6 to -4 (4-6 days before transplant).